Effects of PPARgamma and combined agonists on the urinary tract of rats and other species.
about
Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysisThiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysisRisk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.Cohort study of pioglitazone and cancer incidence in patients with diabetesIdealized PPARγ-Based Therapies: Lessons from Bench and BedsideThe risk of bladder cancer in korean diabetic subjects treated with pioglitazone.Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma AgonistsHistopathology of the urinary bladders of cynomolgus monkeys treated with PPAR agonists.Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) useExamining the safety of PPAR agonists - current trends and future prospects.Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies.Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis.Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies.Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells.Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist.Strain-related differences in urine composition of male rats of potential relevance to urolithiasis.Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event.Raf inhibition causes extensive multiple tissue hyperplasia and urinary bladder neoplasia in the rat.Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis.Trans-species comparison of PPAR and RXR expression by rat and human urothelial tissues.Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study.Assessment of Urinary Metabolite Excretion After Rat Acute Exposure to Perfluorooctanoic Acid and Other Peroxisomal Proliferators
P2860
Q27002540-F14D6436-846D-4081-9210-95EFE213322AQ34065266-5FC428F2-0101-413D-B610-AE9593073BABQ34628009-D750C009-F8F8-4E0B-BC4E-32AD8851C05BQ34718437-2A5F219D-6822-460B-8601-F4245C69A8F4Q36056207-5A8FD2E1-59D8-40DD-BACB-CEB1012847CCQ36365241-7DD502FC-CBFC-4232-A5DB-8DFF4A70D750Q37077098-2425FB1B-BB0A-440C-9D04-E71049F76BB0Q37262697-CDEFF037-68E2-4CF2-8577-4B5FE506313FQ37517909-47E13286-3103-4A89-8F1E-00879CE59C61Q37607679-FD945D70-8EF3-4B24-843E-E606D91967BAQ38058381-75227D54-2EA7-48AE-A066-6ED5C64D51B4Q38061184-15B42C33-0F71-48BA-886B-EDC6EB6F41D5Q38122640-1B351870-2452-4CA5-BF20-AC5E8D13EB48Q38250185-67980E34-5C28-4C53-90B6-B3FF30C71451Q38641190-85D03F15-5F11-49A6-B1CB-B4B9EE03D354Q38651175-E7864963-F43B-429F-BFCA-6D76C62E8E71Q38726257-C6CD9303-FC74-4167-984F-87FCF36FDEBBQ40141299-4BAE005F-D79B-4B38-AEBB-AADD5240B313Q42723223-944C8ABC-074D-45D4-AEE3-29C84E20FB17Q42968936-6F192ECB-8B1A-4165-B94D-5DFC39B050F4Q43287595-7C817F4F-C6F1-4D02-A427-7BD81E3847CCQ46043672-A448D538-E3B5-4AD7-A738-A580C43360F8Q46599209-B016FCA5-4786-4995-9B41-A8BF8D727931Q51449752-5AA3F468-6519-46E8-AC24-1309DA446787Q51757343-DB3860B3-AFE5-439E-A570-7B4DB87828C0Q52594525-A6BB748C-1EDA-49E6-82AC-CEB3E0165FE4Q53321831-064E5728-BE4A-4AFE-945A-D5B2E03F3F55Q53338744-985ABC55-C868-446C-9609-62356D2E6E43Q55356554-C0C58D23-D51A-499C-A6E7-B9B58B2C9CF9Q57705270-64B951C4-4336-4798-95F2-2B54590382FB
P2860
Effects of PPARgamma and combined agonists on the urinary tract of rats and other species.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Effects of PPARgamma and combi ...... act of rats and other species.
@ast
Effects of PPARgamma and combi ...... act of rats and other species.
@en
type
label
Effects of PPARgamma and combi ...... act of rats and other species.
@ast
Effects of PPARgamma and combi ...... act of rats and other species.
@en
prefLabel
Effects of PPARgamma and combi ...... act of rats and other species.
@ast
Effects of PPARgamma and combi ...... act of rats and other species.
@en
P2860
P356
P1476
Effects of PPARgamma and combi ...... act of rats and other species.
@en
P2093
Samuel M Cohen
P2860
P304
P356
10.1093/TOXSCI/KFI266
P577
2005-07-27T00:00:00Z